Chromatography Research International

Chromatography Research International / 2011 / Article

Research Article | Open Access

Volume 2011 |Article ID 278923 | https://doi.org/10.4061/2011/278923

Dipti B. Patel, Natubhai J. Patel, Sejal K. Patel, Paresh U. Patel, "Validated Stability Indicating HPTLC Method for the Determination of Dutasteride in Pharmaceutical Dosage Forms", Chromatography Research International, vol. 2011, Article ID 278923, 5 pages, 2011. https://doi.org/10.4061/2011/278923

Validated Stability Indicating HPTLC Method for the Determination of Dutasteride in Pharmaceutical Dosage Forms

Academic Editor: Osama Y. Al-Dirbashi
Received12 Mar 2011
Accepted12 May 2011
Published21 Jul 2011

Abstract

This paper describes simple, sensitive, precise, specific, and stability-indicating high-performance thin-layer chromatographic method for the determination of dutasteride (DUTA) in bulk and tablet formulation. Validation was carried out in compliance with International Conference on Harmonization guidelines. The thin-layer chromatographic method employed aluminium plates precoated with silica gel G60F254 as stationary phase. The solvent system consisted of toluene/methanol/triethylamine (9 : 2 : 1, v/v/v). This solvent system was found to give compact spots for dutasteride with 𝑅 𝑓 value 0.71 ± 0.01. Densitometric analysis of DUTA was carried out in the absorbance mode at 274 nm. Linear regression analysis showed good linearity ( 𝑟 2 = 0 . 9 9 8 9 ) with respect to peak area in the concentration range of 200–3000 ng per spot. The method was validated for precision, accuracy, specificity, and robustness. Pure drug was subjected to acid and alkali hydrolysis, oxidation, photo degradation, dry heat and wet heat treatment. The drug underwent degradation under acidic, basic, oxidative, and wet heat conditions. The degraded products were well separated from the pure drug. Statistical analysis proved that the method is reproducible and selective for estimation of DUTA in bulk and tablets. As the method could effectively separate the drugs from their degradation products, it can be employed as a stability indicating method.

1. Introduction

Dutasteride, 5α,17β-N-{2,5 bis(trifluoromethyl)phenyl}-3-oxo-4-azaandrost-1-ene-17-carboxamide [1], is a selective inhibitor of 5α-reductase, an intracellular enzyme that converts testosterone to DHT and is used for the treatment of patients with symptomatic benign prostatic hyperplasia [24]. Several bioanalytical and analytical methods have been reported for the analysis of DUTA. These include LC-MS method for determination of DUTA in human plasma [5], HPLC and HPTLC methods in pure powder and formulations [6, 7], and stability-indicating LC methods in pharmaceutical dosage form [8]. Recently, liquid chromatography coupled to mass spectrometry (LC-MS-MS) [9] and UV-visible spectrophotometric [10] methods have been reported for the simultaneous estimation of tamsulosin and dutasteride in plasma and formulations, respectively.

The present work deals with development and validation of stability indicating HPTLC method for the quantitative analysis of DUTA and its stress degradation products. The aim of the present work was to develop an economic, accurate, specific, reproducible, and stability-indicating HPTLC method using densitometric detection for the determination of DUTA in the presence of its degradation products, either in bulk form or in tablets.

2. Experimental

2.1. Instruments and Apparatus

A Camag HPTLC instrument consisting of Linomat V automatic spotter equipped with a 100 μL syringe, Scanner-III, flat-bottom twin-trough developing chambers, and viewing cabinet with dual wavelength UV lamps (Camag, Muttenz, Switzerland) were used. HPTLC plates used were of aluminium backed silica gel G60F254 with 0.2 mm thickness, 2 0 × 1 0  cm (E. Merck, Darmstadt, Germany, supplied by Anchrom Technologists, Mumbai). Sartorius CP224S analytical balance (Gottingen, Germany) and ultrasonic cleaner (Frontline FS 4, Mumbai, India) were used during the research work.

2.2. Reagents and Materials

Dutasteride pure powder with 99.98% purity was kindly gifted by Intas pharmaceutical Ltd. All the reagents used during the study were procured from S. D. Fine Chemical and were of analytical grade. Tablets were purchased from the local pharmacy.

2.3. Chromatographic Conditions

Before analysis, HPTLC plates were cleaned by predevelopment with methanol and activated at 110°C for 5 min for solvent removal. Solutions of DUTA were applied to plates ( 1 0 × 1 0  cm) by means of a Linomat V automatic spotter equipped with a 100 μL syringe and operated with settings of band length, 6 mm; distance between bands, 10 mm; distance from the plate edge, 10 mm; and distance from the bottom of the plate, 10 mm. The plate was developed in a twin-trough chamber previously saturated for 30 min with the mobile phase, toluene/methanol/triethylamine (9 : 2 : 1, v/v/v) to 8.5 cm. Densitometric scanning was performed using a Camag TLC scanner III in the reflectance-absorbance mode at 274 nm for all measurements and operated by the CATS software.

2.4. Preparation of Standard Solution

Accurately weighed 10 mg of DUTA was transferred to a 10 mL volumetric flask and dissolved in and diluted up to the mark with methanol to obtain a standard solution of DUTA (1000 μg/mL). From this solution, 2 mL was further diluted to 10 mL with methanol to obtain a working standard solution of DUTA (200 ng/μL).

2.5. Method Validation

The HPTLC method was validated as per ICH guidelines [11].

2.5.1. Linearity

Accurate quantities from working standard solutions (1, 2, 4, 6, 8, 10, and 15 μL) were applied to the TLC plate to give bands containing 200–3000 ng of DUTA per spot, and the plate was developed, using the previously described optimized mobile phase, and scanned. The experiment was repeated for five times. The calibration curves were constructed by plotting peak areas versus concentrations.

2.5.2. Accuracy (% Recovery)

Accuracy of the method was determined by standard addition method in which the known amount of standard DUTA solutions were added to preanalyzed tablet solution. These amounts corresponded to 50, 100, and 150% of the amounts claimed on the label. The amounts of DUTA were estimated by applying these values to the regression equation of the calibration curve. Accuracy study was performed for five times, and % recovery of DUTA was calculated.

2.5.3. Method Precision (Repeatability)

The precision of the instruments was checked by repeated spotting of same standard solution of DUTA and repeated scanning of the same spot ( 𝑛 = 6 ) of DUTA without changing the position of plate for the HPTLC method. Repeatability is reported in terms of relative standard deviation (% RSD).

2.5.4. Intermediate Precision (Reproducibility)

The intraday and interday precisions of the proposed methods were determined by estimating the corresponding responses 3 times on the same day and on 3 different days for 3 different concentrations of DUTA (800, 1200, and 1600 ng/spot). The results are reported in terms of relative standard deviation (% RSD).

2.5.5. Limit of Detection and Limit of Quantification

The limit of detection (LOD) and the limit of quantification (LOQ) of the both drugs were found by visual inspection.

2.5.6. Robustness of the Method

Robustness of the proposed method was estimated by changing different conditions like mobile phase composition (±0.2 mL for each component), mobile phase volume (varied ±3%), scanning wavelength ±1 nm, peak areas were measured after development of plate, and % RSD was calculated. A concentration level of 1000 ng per band was employed.

2.5.7. Solution Stability

The stability of standard solutions was tested after 0, 6, 12, 24, 48, and 72 h of storage. The stability of the solutions was determined by comparing peak area percentage and peak purity at 1000 ng per band.

2.6. Analysis of DUTA in Tablets

To determine the content of DUTA in conventional tablets, 30 tablets were weighed, their mean weight determined and finely powdered. Powder equivalent to 10 mg of DUTA was transferred into a 100 mL volumetric flask containing 20 mL methanol, sonicated for 30 min, and diluted to the mark with methanol. The resulting solution was centrifuged for 10 min, and the supernatant was diluted with methanol to obtain 100 ng/μL of the drug. 10 μL of this solution was applied to the HPTLC plate at 1000 ng per spot and followed by development. Analysis was carried out in triplicate, peak areas were measured at 274 nm, and sample concentrations calculated. The potential interference from excipients was also examined.

2.7. Forced Degradation of Dutasteride

Decomposition studies were performed in solutions containing DUTA at a concentration of 1 mg/mL. Samples were withdrawn at suitable time intervals and subjected to HPTLC analysis. The drug was subjected under different stress conditions as follows.

2.7.1. Acid- and Base-Induced Degradation

1 mL of the methanolic stock solution was diluted with each of 1 N HCl and 1 N NaOH to 25 mL separately and was refluxed at 50°C.

2.7.2. Oxidative Degradation

1 mL of the methanolic stock solution was diluted with 30% (v/v) of hydrogen peroxide to 25 mL. The solution was refluxed at 50°C.

2.7.3. Wet Heat Degradation

1 mL of the methanolic stock solution was diluted with distilled water 25 mL and was refluxed in a boiling water bath to assess wet heat degradation.

2.7.4. Dry Heat Degradation

For dry heat degradation, the standard drug was placed in an oven at 100°C for 24 h.

2.7.5. Photostability

The photochemical stability of the drug was studied by exposing the solution to direct sunlight for 48 h kept on a terrace. For UV degradation analysis, the solution was exposed to UV radiation for 48 h.

3. Results and Discussion

3.1. Optimization of the Chromatographic Conditions

The TLC procedure was optimized with a view to develop a stability indicating assay method used for the quantification of the DUTA in pharmaceutical tablets. Both the pure drug and the degraded products were spotted on the TLC plate and run in different solvent systems. Initially, different solvent systems were tried but Toluene/methanol/triethylamine (9 : 0.5 : 0.1, v/v/v) gave good resolution with the value of 0.32 for DUTA, but typical peak nature was missing; moreover, it was felt necessary to increase better resolution of impurities. Finally, this mobile phase was optimized to achieve good peak symmetry and better separation of DUTA from degradation peaks obtained under different stressed conditions. The spot appeared to be more compact with a more symmetrical peak shape when TLC plates were pretreated with methanol and activated at 110°C for 5 min. Well-defined standard spots along with its degradation products were obtained when the chamber saturation time was optimized to 30 min at 25°C temperature.

Good resolution and considerable high 𝑅 𝑓 value ( 0 . 7 1 ± 0 . 0 1 ) were obtained for DUTA using optimized mobile phase toluene/methanol/triethylamine (9 : 2 : 1, v/v/v) with densitometric scanning at 274 nm (Figure 1).

3.2. Validation of the Method

The calibration plot was linear over a concentration range of 200–3000 ng per spot for DUTA. A good linear relationship observed over this range ( 𝑟 2 = 0 . 9 9 8 9 ± 0 . 0 0 6 9 , s l o p e = 1 . 7 5 3 ± 0 . 0 5 , i n t e r c e p t = 6 0 0 . 3 8 ± 0 . 2 4 2 ) indicated that the method is linear. Repeatability of sample application and sample measurement was expressed as % RSD and was found to be 0.53% and 0.39% for six replicate determinations. The low values of % RSD indicate that the proposed method is repeatable. The % RSD value obtained for intraday and interday variation were 0.684–1.048% and 1.012–1.224%, respectively, which indicates that proposed method is precise. RSD of peak areas during robustness studies were calculated for changes in parameters and were less than 2% which indicates that this method is robust and reproducible. LOD and LOQ values were found to be 10 and 50 ng per spot, respectively, and pointed towards adequate sensitivity of the method. Peak purity for DUTA was assessed by comparing spectra acquired at the start (S), apex (M), and end (E) of the peak obtained from the scanning of spot, that is, 𝑟 ( 𝑆 , 𝑀 ) = 0 . 9 9 9 6 and 𝑟 ( 𝑀 , 𝐸 ) = 0 . 9 9 9 4 . The high value of 𝑟 2 indicates specificity of the method. Accuracy was determined on previously analysed formulations after spiking with 50, 100, and 150% of the additional drug. Mean recovery obtained is 9 9 . 8 1 % ± 0 . 6 9 7 . Validation parameters are summarized in Table 1.


ParametersValue

Linearity and range200–3000 ng/spot
Correlation coefficient ( 𝑟 2 )0.9989
Limit of detection10 ng/spot
Limit of quantification50 ng/spot
% accuracy ± SDa ( 𝑛 = 3 )99.81%  ± 0.697
Precision (% RSDb)
Repeatability of sample application ( 𝑛 = 6 )0.53%
Repeatability of sample measurement ( 𝑛 = 6 )0.39%
Intraday ( 𝑛 = 3 )0.684%–1.048%
Interday ( 𝑛 = 3 )1.012%–1.224%
RobustnessRobust
SpecificitySpecific
% assay ± SDa99.49%  ± 0.56

aStandard deviation; brelative standard deviation.
3.3. Solution Stability

There was no indication of degradation in sample solutions of DUTA as revealed by peak purity data and from the value of RSD (<2%) for peak areas of bands of solution stored at different times. The solution was found to be stable at ambient temperature for 72 h, and no unknown peaks were observed.

3.4. Analysis of Formulated Tablets

A single band was observed in samples extracted from tablets, and there was no interference from the excipients which might have been present in the tablets. The amount of DUTA obtained in tablets is in good agreement with label claim. The content of DUTA in tablets was found to be 99.49% with standard deviation 0.56. It was therefore inferred that there is no intereference of excipients during the analysis of DUTA normally present in tablets. Thus the method can be applied for the routine analysis of DUTA in pharmaceutical formulations.

3.5. Stability Indicating Properties

The chromatograms obtained after exposure of solution of DUTA (2000 ng/spot) to acidic and alkaline conditions (Figure 2), oxidative conditions (Figure 3), and wet heat degradation showed well separated bands of DUTA from additional bands of degradation impurities at different 𝑅 𝑓 values. For samples of same concentration that were subjected to sun light, ultraviolet (UV) light at 254 nm, and dry heat, no additional band was detected which indicated stability of DUTA under these conditions. Spots obtained from degradation products were well resolved from the active ingredient. Peak purity of these spots of DUTA resolved during stability study was assessed by comparing the respective spectra at peak start, peak middle, and peak end, that is, 𝑟 ( 𝑆 , 𝑀 ) and 𝑟 ( 𝑀 , 𝐸 ) . The peak purity data indicated that peaks of DUTA resolved after application of stress conditions were pure. Degradation products obtained under different stress conditions are summarized in Table 2.


Stress conditions 𝑅 𝑓 values of degradation productsPeak purity data 𝑟 ( 𝑆 , 𝑀 ) , 𝑟 ( 𝑀 , 𝐸 )

Acid hydrolysis, 0.1 N HCl, refluxed for 8 h at 50°C0.550.9991, 0.9996
Alkaline hydrolysis, 1 N NaOH, refluxed for 4 h at 50°C0.26, 0.550.9998, 0.9994
Oxidation (H2O2, 30% v/v), refluxed for 3 h at 50°C0.39, 0.550.9996, 0.9995
Wet heat, refluxed for 10 h at 100°C0.550.9993, 0.9996
Dry heat, heated in oven at 100°C for 24 hNot detected0.9990, 0.9994
Day light, exposed to sunlight for 48 hNot detected0.9993, 0.9996
UV light, exposed to UV light (254 nm) for 48 hNot detected0.9995, 0.9997

4. Conclusion

The developed HPTLC procedure was simple, precise, specific and accurate. Separation of DUTA from degradation products confirmed stability indicating properties of this method. Statistical analysis indicated that the method was reproducible and selective for the analysis of DUTA in bulk drug and in tablets without interference from excipients. This methodology may also be applied to the study of degradation kinetics and for its determination in plasma and other biological fluids.

Acknowledgment

All authors are greatly thankful to S. K. Patel College of Pharmaceutical Education and Research, Ganpat Vidyanagar, Kherva, for providing facilities to carry out the work.

References

  1. The Merck Index, Merck Research Laboratories, Division of Merck & Co., Whitehouse Station, NJ, USA, 14th edition, 2006.
  2. S. C. Sweetman, Martindale: The Complete Drug Reference, Pharamceutical Press., The Royal Pharmaceutical Society of great Britain, 34th edition, 2005.
  3. C. Page, M. Walker, and M. Curtis, Integrated Pharmacology, Mosby, New York, NY, USA, 2002.
  4. M. Marberger, “Drug insight: 5α-reductase inhibitors for the treatment of benign prostatic hyperplasia,” Nature Clinical Practice Urology, vol. 3, no. 9, pp. 495–503, 2006. View at: Publisher Site | Google Scholar
  5. S. S. Kamat, V. B. Choudhari, V. T. Vele, and S. S. Prabhune, “Determination of dutasteride by LC: validation and application of the method,” Chromatographia, vol. 67, no. 11–12, pp. 911–916, 2008. View at: Publisher Site | Google Scholar
  6. D. V. S. Rao and P. Radhakrishnanand, “Stress degradation studies on dutasteride and development of a stability-indicating HPLC assay method for bulk drug and pharmaceutical dosage form,” Chromatographia, vol. 67, no. 9–10, pp. 841–845, 2008. View at: Publisher Site | Google Scholar
  7. N. V. S. Ramakrishna, K. N. Vishwottam, S. Puran, M. Koteshwara, S. Manoj, and M. Santosh, “Selective and rapid liquid chromatography-tandem mass spectrometry assay of dutasteride in human plasma,” Journal of Chromatography B, vol. 809, no. 1, pp. 117–124, 2004. View at: Publisher Site | Google Scholar
  8. S. K. Sudhir, B. C. Vishal, T. V. Vinayak, and S. P. Swarup, “Determination of dutasteride from its bulk drug and pharmaceutical preparations by high performance thin layer chromatography,” Asian Journal of Chemistry, vol. 20, no. 7, pp. 5514–5518, 2008. View at: Google Scholar
  9. S. Agarwal, K. V. Gowda, A. K. Sarkar et al., “Simultaneous determination of tamsulosin and dutasteride in human plasma by LC-MS-MS,” Chromatographia, vol. 67, no. 11–12, pp. 893–903, 2008. View at: Publisher Site | Google Scholar
  10. V. V. Pande, “Simultaneous estimation of Tamsulosin hydrochloride and Dutasteride in combined dosage form by UV spectroscopy method,” Journal of Pharmacy Research, vol. 3, p. 15, 2009. View at: Google Scholar
  11. “Validation of analytical methods: methodology,” in Proceedings of the 3rd International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH '96) Guideline on Validation of Analytical Procedure-Methodology, Geneva, Switzerland, 1996. View at: Google Scholar

Copyright © 2011 Dipti B. Patel et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder
Views2287
Downloads3709
Citations

Related articles

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.